GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2012

FDA Clears First New G-CSF Neutropenia Therapy in 10 Years

  • FDA approved Teva Pharmaceuticals’ short-acting recombinant G-CSF product tbo-filgrastim (XM02 filgrastim) for reducing the duration of severe neutropenia in patients with nonmyeloid cancers receiving chemotherapy that impacts on the bone marrow. Teva says tbo-filgrastim is the first new G-CSF to be sanctioned in the U.S. for over 10 years.

    Filgrastim is already marketed in Europe under the trade name Tevagrastin®, a biosimilar of Neuopogen®. However, FDA submission of tbo-filgrastim was made as a Biologics License Application, as a biosimilar approval pathway hadn’t been established at the time of filing, Teva notes.

    Approval in the U.S. was based on studies in which patients treated using tbo-filgrastim during their first 21-day chemotherapy cycle demonstrated a significantly reduced average duration of neutropenia, from 3.8 days (with placebo therapy) to 1.1 day.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?